Pharmaceutical Executive December 2012

December 2012 | Volume 0, Issue 0
Features
By Pharmaceutical Executive Editors
At two years and counting, what's the secret of success in negotiating pricing under the new AMNOG legislation?
By Pharmaceutical Executive Editors
Eli Lilly's pioneering pact with leading CRO Covance made big news when it happened. Four years later, both parties can point to metrics that suggest the benefit is mutual.
Europe's chief regulator charts a strategy from many moving parts. Dr Guido Rasi talks to Pharm Exec's William Looney.
From the Editor
The calendar says its wrap-up time, not just for gifts but for some of the trends that shaped the industry—for good or bad—in 2012.
Column
Ben Comer profiles 10 innovative technologies designated as new and revolutionary tools for the treatment of disease and disability.
By Pharmaceutical Executive Editors
How to stop worrying and learn to love the data.
Tax and budget decisions will shape the healthcare market and drug research and regulation.
native1_300x100
lorem ipsum